BNET Industries

Market Cap:$36.9M
Last Fiscal Year Sales:$412.0K
  • Public
  • US
Dow Jones Description

.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The company's primary focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomer. Initial target areas of application for the company's drug delivery technology include anti-nausea, pain management, anti-inflammation and DNA/RNAI applications.

President & Chief Executive Officer
Ronald J. Prentki
Number of Employees 33
Contact Information

123 Saginaw Dr

Redwood City, California 94063

www.appharma.co...

(650) 366-2626

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • A.P. Pharma Reports Third Quarter 2009 Financial Results

    11/16/09 - Financial Announcement - View Story

  • A.P. Pharma, Merial in license agreement

    9/15/09 - Joint Venture / Alliance - View Story

Decision Makers

Name (plus bio) Position
Ronald J. Prentki President & Chief Executive Officer
Gordon Sangster Cfo
Michael Connell Chief Operating Officer and Chief Financial Officer and Director
Michael O'Connell Coo
Stephen C. Whiteford Chief Financial Officer and Vice President, Finance
John Barr Senior Vice President of R & D
Anastassios Retzios Vice President, Clinical Development
Jorge Heller Principal Scientist
Arthur T. Taylor Director
Gregory H. Turnbull Director
Toby Rosenblatt Director

Board of Directors

Name (plus bio) Position
Peter Riepenhausen Board of Directors
Robert L. Zerbe Board of Directors

Ronald Prentki joined us in July 2008 as President, Chief Executive Officer and a director. His most recent prior responsibility was with Easton Healthcare Ventures, LLC, a business development and consulting company he founded in 2005. Previously, he served for seven years as President and on the board of directors at Progenics Pharmaceuticals, Inc., a biopharmaceutical company focusing on the development of products for HIV, cancer and supportive care. Prior to joining Progenics, Mr. Prentki acquired significant pharmaceutical industry experience while serving as Vice President of Business Development and Strategic Planning for the U.S. division of Hoffmann-La Roche; Vice President of Business Development for Sanofi Pharma & Sterling Drug; and in various management positions at Bristol-Myers Squibb and Miles Laboratories. He earned his MBA at the University of Detroit, and holds an undergraduate degree in Microbiology and Public Health from Michigan State University.

Organization Position Status
A.P. Pharma, Inc. President & Chief Executive Officer Current
A.P. Pharma, Inc. Board of Directors Current
Progenics Pharmaceuticals, Inc. President Former
Bristol-Myers Squibb Company Director of Cardiovascular Products & Manager of Anticancer Products Former
Progenics Corp Limited Former
Progenics Pharmaceuticals, Inc. Board of Directors Former
University of Detroit Mercy School of Law MBA Former
Michigan State University Bachelor's Degree, Microbiology and Public Health Former

Mr. Sangster, 55, joined Micrus in November 2007 as our Chief Financial Officer. He most recently served as Vice President of Finance and Chief Financial Officer of HemoSense, Inc., a publicly traded point-of-care clinical diagnostics company. From August 2000 through October 2006, Mr. Sangster was Chief Financial Officer of A.P. Pharma, Inc., a publicly traded specialty pharmaceutical company. From April 1993 to July 2000, he served as A.P. Pharma's vice president of finance and controller. He is a member of the Institute of Chartered Accountants in England and Wales

Organization Position Status
Micrus Endovascular Corporation Chief Financial Officer Current
A.P. Pharma, Inc. Cfo Current
A.P. Pharma, Inc. Vice President of Finance Current
A.P. Pharma, Inc. Board of Directors Current
HemoSense, Inc. Vice President of Finance & Chief Financial Officer Former
Raychem Manager Former
A.P. Pharma, Inc. Corporate Controller Former
Coopervision, Inc. Controller Former

Organization Position Status
A.P. Pharma, Inc. Chief Operating Officer and Chief Financial Officer and Director Current

Organization Position Status
A.P. Pharma, Inc. Coo Current
A.P. Pharma, Inc. Director Current
A.P. Pharma, Inc. President & CEO Former
Coopervision, Inc. Former

Organization Position Status
A.P. Pharma, Inc. Chief Financial Officer and Vice President, Finance Current
The Cooper Companies, Inc. Vice President Current
California State University, Los Angeles B.S. In Business Administration Former

John Barr joined A.P. Pharma in 1997, and has served as a corporate officer since 2000, and was most recently promoted to Senior Vice President, Research & Development in September 2007. Dr. Barr has played a key role in evaluating and developing the potential of our novel delivery systems. Prior to joining us, he worked as the director of Biopharmaceutics for Cortech, Inc, a Denver-based biotech firm focused on the development of novel anti-inflammatory agents. In that capacity, he was involved with both the research and development aspects of the company's intravenous and oral programs. Dr. Barr received his Ph.D. in pharmacology from the University of Glasgow in Scotland, after which he pursued postdoctoral studies at the University of Arizona.

Organization Position Status
A.P. Pharma, Inc. Senior Vice President of R & D Current
A.P. Pharma, Inc. Director Current
Kent International Holdings Inc director of Biopharmaceutics Former
Biopharmaceutics Corporation Director Former
University of Glasgow Ph.D. In Pharmacology Former
The University of Arizona Postdoctoral Former

Organization Position Status
A.P. Pharma, Inc. Vice President, Clinical Development Current
Questcor Pharmaceuticals, Inc. Former
Global Clinical Research Corp Director Former
University of Edinburgh Ph.D. In Molecular Biology Former

Jorge Heller, Principal Scientist, joined A.P. Pharma in 1993 from SRI International, where he served as director of the Controlled Release and Biomedical Polymers department. Prior to that, he was Director of Physical Sciences at Alza Corporation where he began his ongoing research in controlled drug release. Dr. Heller is a past president of the Controlled Release Society. He was visiting professor at the University of Geneva in 1988, visiting professor at the University of Keele in 1989 and visiting professor at the University of Utah in 1990. He is the author of over 135 publications and 30 patents. He received a B.S. degree in chemistry from the University of California at Berkeley and a Ph.D. degree in organic chemistry from the University of Washington in Seattle.

Organization Position Status
A.P. Pharma, Inc. Principal Scientist Current
SRI International director of the Controlled Release and Biomedical Polymers Former
Alza Technologies Corp Director of Physical Sciences Former
University of Geneva Visiting Professor Former
University of Keele Visiting Professor Former
University of Utah Visiting Professor Former
ALZA Corporation Former
University of Washington Ph.D. Degree In Organic Chemistry Former
University of California, Berkeley B.S. Degree In Chemistry Former

Arthur Taylor has served as a member of our board of directors since May 2006. Mr. Taylor has over 20 years financial and operating experience in the medical device, pharmaceutical and technology industries. From November 2007 until June 2008, he served as Vice President, General Manager Kyphon Products and Interspinous Decompression Devices, Spinal & Biologics Business, Medtronic Inc. Prior to the acquisition of Kyphon by Medtronic in 2007, he was Chief Operating Officer of Kyphon Inc., having previously served as Chief Financial Officer of that organization from 2004 to 2006. Before joining Kyphon in 2004, he served as Chief Financial Officer for Terayon, Inc., Evolve Software, Inc., Docent, Inc. and ReSound Corporation. He has also held senior financial positions with 3Com Corporation and Allergan, Inc.

Organization Position Status
A.P. Pharma, Inc. Director Current
Xtent Inc. Board of Directors Current
Terayon Communication Systems, Inc. Chief Financial Officer Former
Resound Corp Chief Financial Officer Former
Kyphon, Inc. Chief Operating Officer Former
3Com Corporation Vice President, Corporate Treasurer Former
University of Southern California M.B.A. degree Former
San Diego State University B.S. in Corporate Finance Former

Mr. Turnbull was elected to the position of Chairman of the Board in September 2005; he has served as a Director of Planar since 1986. He currently is self-employed as a private investor and a consultant. Mr. Turnbull was a partner of Cable & Howse Ventures, a venture capital firm, from 1983 to 1991 and served as an investment banker with Morgan Stanley & Co. and White, Weld & Co. before 1983. Mr. Turnbull also serves on the Board of Directors of A.P. Pharma, Inc. He received a BS in Chemical Engineering from Oregon State University and an MBA from Stanford University.

Organization Position Status
Planar Systems, Inc. Chairman of the Board Current
A.P. Pharma, Inc. Director Current
Planar Systems, Inc. Director Current
Clarity Visual Systems, Inc. Director Current
A.P. Pharma, Inc. President, CEO & Director Former
Morgan Stanley Former
Stanford University MBA Former
Oregon State University BS In Chemical Engineering Former

Toby Rosenblatt has served as a member of our board of directors since September 1983. Mr. Rosenblatt has been President of Founders Investments, Ltd., a private investment limited partnership since 1999. Mr. Rosenblatt also serves as a director of the BlackRock Open End Mutual Funds and is a trustee of numerous civic and educational institutions.

Organization Position Status
A.P. Pharma, Inc. Board of Directors Current
Sonitus Medical, Inc. Board of Directors Current
Orthoclear, Inc. Director Current
Resound Corp Chief Executive Officer Former
Resound Corp President Former
Align Technology, Inc. Chairman Former

Organization Position Status
Quatrx Pharmaceuticals Co Chief Executive Officer Current
Aastrom Biosciences, Inc. Director Current
Anesiva Inc. Board of Directors Current
A.P. Pharma, Inc. Board of Directors Current
Quatrx Pharmaceuticals Co Board of Directors Current
Pfizer Inc. Senior Vice President of Global Research and Development Former
Quatrx Pharmaceuticals Co Founder Former
Parke-Davis & Company Limited Former
Eli Lilly and Company Former
Corporate Governance Chair Former
Maxim Pharmaceuticals, Inc. Director Former
Indiana University M.D. Former
Indiana University School of Medicine M.D. Former
Indiana University Degree Former

Organization Position Status
Founders Investments Ltd. President Current
The James Irvine Foundation Vice Chair Current
Pherin Director Current
Forward Management, LLC Director Current
A.P. Pharma, Inc. Director Current
Founders Investments Ltd. General Partner Former
San Francisco Day School Trustee Former
California Pacific Medical Center Former
Center for The Arts Board of Directors Former
San Francisco Arts Commission Board of Directors Former
San Francisco Art Institute Board of Directors Former
Stanford University Master of Business Administration from the Graduate School Former

Executive News

  • Micrus Endovascular to Present at September Investment Conferences

    Reuters - 9/03/09 - View Story

  • Fearing the loss of a massive collection

    Los Angeles Times - 8/07/09 - View Story

  • S.F. art community fears loss of Gap founder's massive collection

    Los Angeles Times - 8/06/09 - View Story

advertisement
     APPA $0.94 +0.01 (1.56% )
Average Volume 55,819
Shares Outstanding 39.38M
Market Cap 37.0M
Year High 1.21
Year Low 0.3
Earnings Per Share -0.39
P/E Ratio -2.41
Dividend N/A
Yield N/A
advertisement
Click Here